-
公开(公告)号：US06270984B1
公开(公告)日：2001-08-07
申请号：US09540245
申请日：2000-03-31
IPC分类号： G01N3383
CPC分类号： C07K14/70503 , A61K38/00 , C07K14/4702 , G01N33/566 , G01N33/68 , G01N2333/43573 , G01N2500/02
摘要： Disclosed are methods and compositions for identifying agents which modulate the interaction of Robo and a Robo ligand and for modulating the interaction of Robo and a Robo ligand. The methods for identifying Robo:ligand modulators find particular application in commercial drug screens. These methods generally comprise (1) combining a Robo polypeptide, a Slit polypeptide and a candidate agent under conditions whereby, but for the presence of the agent, the Robo and Slit polypeptides engage in a first interaction, and (2) determining a second interaction of the Robo and Slit polypeptides in the presence of the agent, wherein a difference between the first and second interactions indicates that the agent modulates the interaction of the Robo and Slit polypeptides. The subject methods of modulating the interaction of Robo and a Robo ligand involve combining a Robo polypeptide, a Slit polypeptide and a modulator under conditions whereby, but for the presence of the modulator, the Robo and Slit polypeptides engage in a first interaction, whereby the Robo and Slit polypeptides engage in a second interaction different from the first interaction. In a particular embodiment, the modulator is dominant negative form of the Robo or Slit polypeptide.
摘要翻译： 公开了用于鉴定调节Robo和Robo配体的相互作用并调节Robo和Robo配体的相互作用的试剂的方法和组合物。 用于鉴定Robo：配体调节剂的方法在商业药物筛选中发现具体应用。 这些方法通常包括（1）在条件下组合Robo多肽，狭缝多肽和候选试剂，但是对于所述试剂的存在，所述Robo和狭缝多肽参与第一相互作用，和（2）确定第二相互作用 的Robo和Slit多肽，其中所述第一和第二相互作用之间的差异指示所述试剂调节所述Robo和Slit多肽的相互作用。 调节Robo和Robo配体的相互作用的主题方法包括在条件下组合Robo多肽，狭缝多肽和调节剂，但是对于调节剂的存在，Robo和Slit多肽参与第一相互作用，由此 Robo和Slit多肽参与与第一相互作用不同的第二相互作用。 在一个具体实施方案中，调节剂是Robo或Slit多肽的显性阴性形式。
-
公开(公告)号：US6046015A
公开(公告)日：2000-04-04
申请号：US191647
申请日：1998-11-13
IPC分类号： C12N15/09 , A61K38/00 , A61K38/17 , A61P43/00 , C07K14/47 , C07K14/705 , C07K16/18 , C12N15/12 , G01N33/15 , G01N33/50 , G01N33/566 , G01N33/68 , G01N33/53 , C07K7/08 , C12N5/02
CPC分类号： C07K14/70503 , C07K14/4702 , G01N33/566 , G01N33/68 , A61K38/00 , G01N2333/43573 , G01N2500/02
摘要： Disclosed are methods and compositions for identifing agents which modulate the interaction of Robo and a Robo ligand and for modulating the interaction of Robo and a Robo ligand. The methods for identifying Robo:ligand modulators find particular application in commercial drug screens. These methods generally comprise (1) combining a Robo polypeptide, a Slit polypeptide and a candidate agent under conditions whereby, but for the presence of the agent, the Robo and Slit polypeptides engage in a first interaction, and (2) determining a second interaction of the Robo and Slit polypeptides in the presence of the agent, wherein a difference between the first and second interactions indicates that the agent modulates the interaction of the Robo and Slit polypeptides. The subject methods of modulating the interaction of Robo and a Robo ligand involve combining a Robo polypeptide, a Slit polypeptide and a modulator under conditions whereby, but for the presence of the modulator, the Robo and Slit polypeptides engage in a first interaction, whereby the Robo and Slit polypeptides engage in a second interaction different from the first interaction. In a particular embodiment, the modulator is dominant negative form of the Robo or Slit polypeptide.
摘要翻译： 公开了用于调节Robo和Robo配体的相互作用并用于调节Robo和Robo配体的相互作用的识别剂的方法和组合物。 用于鉴定Robo：配体调节剂的方法在商业药物筛选中发现具体应用。 这些方法通常包括（1）在条件下组合Robo多肽，狭缝多肽和候选试剂，但是对于所述试剂的存在，所述Robo和狭缝多肽参与第一相互作用，和（2）确定第二相互作用 的Robo和Slit多肽，其中所述第一和第二相互作用之间的差异指示所述试剂调节所述Robo和Slit多肽的相互作用。 调节Robo和Robo配体的相互作用的主题方法包括在条件下组合Robo多肽，狭缝多肽和调节剂，但是对于调节剂的存在，Robo和Slit多肽参与第一相互作用，由此 Robo和Slit多肽参与与第一相互作用不同的第二相互作用。 在一个具体实施方案中，调节剂是Robo或Slit多肽的显性阴性形式。
-
公开(公告)号：US08426147B2
公开(公告)日：2013-04-23
申请号：US12325914
申请日：2008-12-01
IPC分类号： G01N33/53
CPC分类号： G01N33/57484 , A01K2267/0331 , C07K14/4702 , C12Q1/6886 , C12Q2600/136 , G01N33/566 , G01N33/57407 , G01N2333/4704 , G01N2333/70567 , G01N2333/9121 , G01N2500/10
摘要： Human ROR genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of ROR are provided.
摘要翻译： 人类ROR基因被鉴定为p21途径的调节剂，因此是与缺陷型p21功能相关的疾病的治疗靶点。 提供了用于鉴定p21调节剂的方法，包括筛选调节ROR活性的药剂。
-
公开(公告)号：US20090149413A1
公开(公告)日：2009-06-11
申请号：US12325914
申请日：2008-12-01
IPC分类号： A61K31/7105 , C12Q1/68
CPC分类号： G01N33/57484 , A01K2267/0331 , C07K14/4702 , C12Q1/6886 , C12Q2600/136 , G01N33/566 , G01N33/57407 , G01N2333/4704 , G01N2333/70567 , G01N2333/9121 , G01N2500/10
摘要： Human ROR genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of ROR are provided.
摘要翻译： 人类ROR基因被鉴定为p21途径的调节剂，因此是与缺陷型p21功能相关的疾病的治疗靶点。 提供了用于鉴定p21调节剂的方法，包括筛选调节ROR活性的药剂。
-
公开(公告)号：US07005411B1
公开(公告)日：2006-02-28
申请号：US09191651
申请日：1998-11-13
申请人： Corey S. Goodman , Thomas Kidd , Guy Tear , Claire Russell , Kevin J. Mitchell
发明人： Corey S. Goodman , Thomas Kidd , Guy Tear , Claire Russell , Kevin J. Mitchell
CPC分类号： A61K38/1709
摘要： The amount of active Robo expressed on a cell is modified by modulating the effective amount of a Comm polypeptide in contact with the cell, whereby the amount of expressed active Robo is modulated inversely with the modulation of the effective amount of the Comm polypeptide in contact with the cell. In a particular embodiment, the Comm polypeptide is provided to the cell by exogenously in a pharmaceutically acceptable composition. In another aspect, the invention provides methods of screening for agents which modulate Robo-Comm interactions. These methods generally involve forming a mixture of a Robo-expressing cell, a Comm polypeptide and a candidate agent, and determining the effect of the agent on the amount of Robo expressed by the cell.
摘要翻译： 通过调节与细胞接触的Comm多肽的有效量来修饰在细胞上表达的活性Robo的量，由此与表达的活性Robo的有效量的调节相反地调节与Comm接触的Comm多肽的有效量 细胞。 在一个具体实施方案中，通过外源地在药学上可接受的组合物中将Comm多肽提供给细胞。 另一方面，本发明提供筛选调节Robo-Comm相互作用的试剂的方法。 这些方法通常涉及形成Robo表达细胞，Comm多肽和候选试剂的混合物，并确定试剂对细胞表达的Robo量的影响。
-
公开(公告)号：US20060160421A1
公开(公告)日：2006-07-20
申请号：US11038708
申请日：2005-01-20
申请人： John Dangler , Matthew Doyle , Thomas Kidd , Bradley Martin , Kevin Przybylski , Jason Stoll
发明人： John Dangler , Matthew Doyle , Thomas Kidd , Bradley Martin , Kevin Przybylski , Jason Stoll
IPC分类号： H01R13/648
CPC分类号： H05K1/0218 , H01B7/0861 , H05K1/0393 , H05K3/4611 , H05K3/4635 , H05K2201/0715 , H05K2201/09318 , H05K2201/09618
摘要： In a flat flex cable, signal lines are surrounded by logic ground planes above and below which are viaed together left and right. The ground planes coupled with the flex cable dielectric determine characteristic the impedance and attenuation of the cable and provide differential signal EMI shielding. All signal layers and logic ground planes are enclosed within the two outermost shield layers which are viaed together left and right and around the connectors to enclose both signal layers and logic ground planes to provide common mode EMI shielding.
摘要翻译： 在扁平柔性电缆中，信号线被上下逻辑接地层包围，左右两侧通过。 与柔性电缆介质耦合的接地层确定电缆的阻抗和衰减特性，并提供差分信号EMI屏蔽。 所有信号层和逻辑接地层都被封闭在两个最外面的屏蔽层内，这两个最外面的屏蔽层一起左右连接并连接在一起，以封闭信号层和逻辑接地层以提供共模EMI屏蔽。
-
7.发明申请公开(公告)号：US20060063710A1
公开(公告)日：2006-03-23
申请号：US10528168
申请日：2003-09-15
申请人： Helen Francis-Lang , Lori Friedman , Thomas Kidd , Siohan Roche , Kim Lickteig
发明人： Helen Francis-Lang , Lori Friedman , Thomas Kidd , Siohan Roche , Kim Lickteig
IPC分类号： A61K38/17 , C12Q1/68 , G01N33/574
CPC分类号： C12Q1/6886 , A61K38/00 , C12Q2600/136 , G01N33/5011 , G01N2333/82
摘要： Human FLJ20647 genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of FLJ20647 are provided.
摘要翻译： 人FLJ20647基因被鉴定为p21途径的调节剂，因此是与缺陷型p21功能相关的病症的治疗靶点。 提供了鉴定p21调节剂的方法，包括筛选调节FLJ20647活性的试剂。
-
公开(公告)号：US20050251870A1
公开(公告)日：2005-11-10
申请号：US10523588
申请日：2003-08-06
申请人： Helen Francis-Lang , Lori Friedman , Thomas Kidd
发明人： Helen Francis-Lang , Lori Friedman , Thomas Kidd
IPC分类号： G01N33/50 , A01K67/00 , A01K67/033 , A61K39/395 , C07K14/47 , C07K14/82 , C12N5/10 , C12N15/09 , C12Q1/02 , C12Q1/48 , C12Q1/68 , G01N33/15 , G01N33/53 , G01N33/574
CPC分类号： A01K67/0339 , A01K2217/05 , A01K2227/706 , C07K14/4702 , C07K14/82 , G01N33/5308 , G01N33/574
摘要： Human CSNK1G genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of CSNK1G are provided.
摘要翻译： 人类CSNK1G基因被鉴定为p21途径的调节剂，因此是与缺陷型p21功能相关的病症的治疗靶点。 提供了鉴定p21调节剂的方法，包括筛选调节CSNK1G活性的试剂。
-
公开(公告)号：US20050059040A1
公开(公告)日：2005-03-17
申请号：US10826812
申请日：2004-04-16
申请人： Corey Goodman , Thomas Kidd , Kevin Mitchell , Guy Tear
发明人： Corey Goodman , Thomas Kidd , Kevin Mitchell , Guy Tear
IPC分类号： C12N15/09 , A61K38/00 , A61K39/395 , A61P25/00 , A61P43/00 , C07K14/475 , C07K14/48 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/18 , C12P21/02 , C12Q1/68 , C07H21/04 , C07K14/705 , G01N33/53
CPC分类号： C07K14/475 , A61K38/00
摘要： Robo1 and Robo2 polypeptides may be produced recombinantly from transformed host cells from the disclosed Robo encoding nucleic acids or purified from human cells. The invention provided isolated Robo hybridization probes and primers capable of specifically hybridizing with the disclosed Robo genes, Robo-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
摘要翻译： Robo1和Robo2多肽可以从所公开的Robo编码核酸的转化的宿主细胞重组产生或从人细胞纯化产生。 本发明提供了能够与所公开的Robo基因，Robo特异性结合剂如特异性抗体特异性杂交的分离的Robo杂交探针和引物，以及在诊断，治疗和生物制药工业中制备和使用主题组合物的方法。
-
公开(公告)号：US06270995B1
公开(公告)日：2001-08-07
申请号：US09540153
申请日：2000-03-31
IPC分类号： C12P2102
CPC分类号： C07K14/70503 , A61K38/00 , C07K14/4702 , G01N33/566 , G01N33/68 , G01N2333/43573 , G01N2500/02
摘要： Disclosed are methods and compositions for identifying agents which modulate the interaction of Robo and a Robo ligand and for modulating the interaction of Robo and a Robo ligand. The methods for identifying Robo:ligand modulators find particular application in commercial drug screens. These methods generally comprise (1) combining a Robo polypeptide, a Slit polypeptide and a candidate agent under conditions whereby, but for the presence of the agent, the Robo and Slit polypeptides engage in a first interaction, and (2) determining a second interaction of the Robo and Slit polypeptides in the presence of the agent, wherein a difference between the first and second interactions indicates that the aget modulates the interaction of the Robo and Slit polypeptides. The subject methods of modulating the interaction of Robo and a Robo ligand involve combining a Robo polypeptide, a Slit polypeptide and a modulator under conditions whereby, but for the presence of the modulator, the Robo and Slit polypeptides engage in a first interaction, whereby the Robo and Slit polypeptides engage in a second interaction different from the first interaction. In a particular embodiment, the modulator is dominant negative form of the Robo or Slit polypeptide.
摘要翻译： 公开了用于鉴定调节Robo和Robo配体的相互作用并调节Robo和Robo配体的相互作用的试剂的方法和组合物。 用于鉴定Robo：配体调节剂的方法在商业药物筛选中发现具体应用。 这些方法通常包括（1）在条件下组合Robo多肽，狭缝多肽和候选试剂，但是对于所述试剂的存在，所述Robo和狭缝多肽参与第一相互作用，和（2）确定第二相互作用 的Robo和Slit多肽，其中所述第一和第二相互作用之间的差异指示所述琼脂调节所述Robo和Slit多肽的相互作用。 调节Robo和Robo配体的相互作用的主题方法包括在条件下组合Robo多肽，狭缝多肽和调节剂，但是对于调节剂的存在，Robo和Slit多肽参与第一相互作用，由此 Robo和Slit多肽参与与第一相互作用不同的第二相互作用。 在一个具体实施方案中，调节剂是Robo或Slit多肽的显性阴性形式。
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.026 秒)
